Although C1 INH has been used for 30 years in Europe and is currently marketed under the name Berinert P®, this plasma-derived C1 esterase inhibitor (human) was recently approved in the United States for the treatment of acute abdominal or facial HAE attacks in adults and adolescents. This evidence concerns the gene SERPING1 and hereditary angioedema.